Company profile JAGX

Jaguar Health Inc
jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the g...lobal marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/ Show More
Quarter analysis & expected interest

There is not enough data for chronic and debilitating diarrhea to provide analysis

Correlation between past revenue and chronic and debilitating diarrhea search interest

There is not enough data for chronic and debilitating diarrhea to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for chronic and debilitating diarrhea to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 16:16:54.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
Mytesi expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
2019119
262
120.2% QoQ
124
-52.7% QoQ
227
83.1% QoQ
2020 106
-10.9% YoY -53.3% QoQ
158
-39.7% YoY 49.1% QoQ
211
70.2% YoY 33.5% QoQ
266
17.2% YoY 26.1% QoQ
2021 166
56.6% YoY -37.6% QoQ
171
8.2% YoY 3.0% QoQ
75
-64.5% YoY -56.1% QoQ
82
-69.2% YoY 9.3% QoQ
2022 63
-62.0% YoY -23.2% QoQ
82
-52.0% YoY 30.2% QoQ
236
214.7% YoY 187.8% QoQ
149
81.7% YoY -36.9% QoQ
2023 118
87.3% YoY -20.8% QoQ
166
102.4% YoY 40.7% QoQ
59
-75.0% YoY -64.5% QoQ
186
24.8% YoY 215.3% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Mytesi search interestLast update: February 09 2024 16:16:53.
Correlation coefficient between keyword and revenue is 0.18
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 16:16:56.

The average 5 years interest of Mytesi was 11.59 per week.
The last year interest of Mytesi compared to the last 5 years has changed by -17.52%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -35.84%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 16:17:01.

After 39 days of this quarter the interest is at 27.0. Based on that we can calculate that during remaining 52 days it will total up to 63.0.
Crofelemer expected interest is significantly lower compared to previous quarter (-62.5%) and same quarter last year (-42.2%).

YearQ1Q2Q3Q4
201955
66
20.0% QoQ
127
92.4% QoQ
41
-67.7% QoQ
2020 68
23.6% YoY 65.9% QoQ
96
45.5% YoY 41.2% QoQ
86
-32.3% YoY -10.4% QoQ
122
197.6% YoY 41.9% QoQ
2021 137
101.5% YoY 12.3% QoQ
84
-12.5% YoY -38.7% QoQ
216
151.2% YoY 157.1% QoQ
24
-80.3% YoY -88.9% QoQ
2022 110
-19.7% YoY 358.3% QoQ
79
-6.0% YoY -28.2% QoQ
44
-79.6% YoY -44.3% QoQ
63
162.5% YoY 43.2% QoQ
2023 109
-0.9% YoY 73.0% QoQ
124
57.0% YoY 13.8% QoQ
105
138.6% YoY -15.3% QoQ
168
166.7% YoY 60.0% QoQ
2024 27
-75.2% YoY -83.9% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Crofelemer search interestLast update: February 09 2024 16:17:01.
Correlation coefficient between keyword and revenue is -0.3
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 16:17:09.

The average 5 years interest of Crofelemer was 7.48 per week.
The last year interest of Crofelemer compared to the last 5 years has changed by 25.94%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 59.66%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Short bowel syndrome with intestinal failure to provide analysis

Correlation between past revenue and Short bowel syndrome with intestinal failure search interest

There is not enough data for Short bowel syndrome with intestinal failure to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Short bowel syndrome with intestinal failure to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for supportive care for diarrhea relief in inflammatory bowel diseases to provide analysis

Correlation between past revenue and supportive care for diarrhea relief in inflammatory bowel diseases search interest

There is not enough data for supportive care for diarrhea relief in inflammatory bowel diseases to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for supportive care for diarrhea relief in inflammatory bowel diseases to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for diarrhea-predominant irritable bowel syndrome to provide analysis

Correlation between past revenue and diarrhea-predominant irritable bowel syndrome search interest

There is not enough data for diarrhea-predominant irritable bowel syndrome to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for diarrhea-predominant irritable bowel syndrome to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for idiopathic/functional diarrhea to provide analysis

Correlation between past revenue and idiopathic/functional diarrhea search interest

There is not enough data for idiopathic/functional diarrhea to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for idiopathic/functional diarrhea to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for NP-300 to provide analysis

Correlation between past revenue and NP-300 search interest

There is not enough data for NP-300 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for NP-300 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 16:17:18.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
Canalevia expected interest is significantly lower compared to same quarter last year (-100.0%) but similar to previous quarter.

YearQ1Q2Q3Q4
201980
156
95.0% QoQ
24
-84.6% QoQ
144
500.0% QoQ
2020 79
-1.2% YoY -45.1% QoQ
39
-75.0% YoY -50.6% QoQ
23
-4.2% YoY -41.0% QoQ
140
-2.8% YoY 508.7% QoQ
2021 183
131.6% YoY 30.7% QoQ
202
417.9% YoY 10.4% QoQ
67
191.3% YoY -66.8% QoQ
114
-18.6% YoY 70.1% QoQ
2022 74
-59.6% YoY -35.1% QoQ
0
-100.0% YoY -100.0% QoQ
89
32.8% YoY inf% QoQ
20
-82.5% YoY -77.5% QoQ
2023 201
171.6% YoY 905.0% QoQ
142
inf% YoY -29.4% QoQ
82
-7.9% YoY -42.3% QoQ
0
-100.0% YoY -100.0% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Canalevia search interestLast update: February 09 2024 16:17:17.
Correlation coefficient between keyword and revenue is -0.4
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 16:17:22.

The average 5 years interest of Canalevia was 7.12 per week.
The last year interest of Canalevia compared to the last 5 years has changed by 5.06%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -8.67%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for chemotherapy-induced diarrhea in dogs to provide analysis

Correlation between past revenue and chemotherapy-induced diarrhea in dogs search interest

There is not enough data for chemotherapy-induced diarrhea in dogs to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for chemotherapy-induced diarrhea in dogs to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for exercise-induced diarrhea in dogs. to provide analysis

Correlation between past revenue and exercise-induced diarrhea in dogs. search interest

There is not enough data for exercise-induced diarrhea in dogs. to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for exercise-induced diarrhea in dogs. to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for JAGX
Earnings date: 2024-03-22 After close
Company name: Jaguar Health Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-08T13:00:00Z

AccessWire
Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule

2026-05-06T13:00:00Z

AccessWire
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

2026-05-04T12:30:00Z

AccessWire
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health

2026-04-29T12:30:00Z

AccessWire
Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs

2026-04-27T13:00:00Z

AccessWire
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split

2026-04-24T12:30:00Z

AccessWire
Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)

2026-04-20T20:15:00Z

AccessWire
Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders

2026-04-13T12:30:00Z

AccessWire
Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs

2026-04-10T00:15:00Z

AccessWire
Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates

2026-04-08T12:30:00Z

AccessWire
Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

2026-04-07T12:30:00Z

AccessWire
Jaguar Health Reports 2025 Financials

2026-04-02T13:00:00Z

AccessWire
Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress

2026-03-18T13:00:00Z

AccessWire
FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

2026-03-11T13:00:00Z

AccessWire
Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

2026-03-09T13:00:00Z

AccessWire
Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants